Safety of long-acting β-agonist (LABA) withdrawal in patients in two clinical asthma trials Source: Annual Congress 2012 - Different ways to phenotype asthma Year: 2012
Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004
Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
Incidence of asthma-related hospitalizations with the addition of salmeterol to an ICS in subjects with asthma: a meta-analysis Source: Eur Respir J 2007; 30: Suppl. 51, 352s Year: 2007
COPD subtypes most likely to benefit from inhaled corticosteroids (ICS): Cluster analysis Source: Annual Congress 2012 - Prevalences and characterstics of obstructive airway disease Year: 2012
Adding montelukast versus doubling the budesonide dose in persistent asthma: a subgroup analysis of the COMPACT study Source: Eur Respir J 2002; 20: Suppl. 38, 388s Year: 2002
Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017
Cardiac events among patients with CV comorbidities: Pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Comparison of cardiovascular safety in a pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Efficacy of indacaterol in COPD is maintained irrespective of inhaled corticosteroid (ICS) use Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Combination of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA) versus similar ICS dose in children and adults with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
Reduction in fatal events with extrafine inhaled corticosteroid (ICS)-containing medications: results of stratified safety pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies. Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018
Cardiovascular effects of a high dose of the budesonide/formoterol single inhaler in asthmatic patients Source: Eur Respir J 2001; 18: Suppl. 33, 54s Year: 2001
Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe-to-very severe COPD Source: Annual Congress 2005 - Therapeutic options for COPD: present and future Year: 2005
Is treatment with ICS and LABA good value for money for COPD? Multinational cost-effectiveness analysis of the TORCH study Source: Eur Respir J 2007; 30: Suppl. 51, 194s Year: 2007
Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide - a cost-effectiveness analysis Source: Eur Respir J 2001; 18: Suppl. 33, 517s Year: 2001
Efficacy and safety of inhaled corticosteroid‘s (ICS) and long-acting beta-agonist‘s (LABA) combination in asthma (A) patients Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Retrospective review of studies shows that patients receiving salmeterol plus ICS have fewer serious asthma exacerbations vs patients on ICS alone, regardless of ethnic origin Source: Eur Respir J 2005; 26: Suppl. 49, 429s Year: 2005
Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler Source: ERJ Open Res 2016: 00106-2015 Year: 2016
Pharmacoeconomic analysis of beclomethasone/formoterol versus fluticasone/salmeterol in the treatment of moderate-severe asthma in Spain Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment Year: 2008